VERASTEM INC (VSTM)

Company Profile

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 57 full-time employees. The company went IPO on 2011-11-08. The Company’s pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced product candidates, Avutometinib (VS-6766) and Defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, but not limited to low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, and melanoma. VS-6766 is an orally available small molecule RAF/MEK clamp. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2) that is being evaluated as a potential combination therapy for various solid tumors.

Company Info

VERASTEM INC

117 Kendrick Street, Suite 500

Cambridge MASSACHUSETTS 02494

P: 17812924200

CEO: Brian M. Stuglik

Employees: 57

Website: https://www.verastem.com/